Date:	7/7/2023
Your Name:	Richard J. Perrin
Manuscript Title:	[Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the v	vork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[□] <b>None</b> [U19AG024904 (Weiner) 09/2022-07/202	7 Institution
	No time limit for this item.		
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1	[□] None	
	above).	P01 AG003991 (Morris) 05/01/19-04/30 P30 AG066444 (Morris) 05/01/20-04/30 U19 AG032438 (Bateman) 09/15/19-06/30 U19AG032438-09S1 (Bateman) 09/2019-06 R01AG054567 (Benzinger)09/15/17-06/30/R01 AG052550 (Benzinger)04/15/18-01/31 R01 AG070883 (Kind, Raji)03/01/21-02/28/R01NS092865 (Xu) 02/01/16-11/30 R01AG054513(Yablonskiy)07/01/17-04/30/R01 NS075321(Perlmutter)05/01/11-04/30/APDA (Perlmutter) 01/01/99-08/2023 R01NS097799 (Kotzbauer)07/2022-06/202 R01AG068319 (Bateman) 09/15/20-05/31/R01 AG053267 (Bateman) 09/01/17-05/31/U19AG069701 (Bu) 06/2021-05/2026	/25 /24 5/2024 /22 /23 /26 /21 /22 <b>D/22 NCE</b> 7  25
		U19NS110456 (Perlmutter) 09/2019-06/20 R01AG058676 (Masters) 09/2018-05/2024 R01AG074909 (Q Wang) 04/2022-01/2027 U19AG07879 (Ertekin-Taner) 03/2023-02/2	NCE

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	[⊠] None		
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	7/14/2023
Your Name:	Tammie Benzinger
Manuscript Title:	[Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None  Time frame: past 36 mont	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this	Specifications/Comments (e.g., if payments were
		relati	onship or indicate none (add rows as needed)	made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	7/14/2023
Your Name:	Adam J Schwarz
Manuscript Title:	[Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial planning  None	Click the tab key to add additional rows.
		Time frame: past 36 mont	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
		Takeda Pharmaceuticals	Minor shareholder
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial	□ None	
	interests	Takeda Pharmaceuticals	Employee
Plea	Please place an "X" next to the following statement to indicate your agreement:		
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/15/2023
Your Name:	Duygu Tosun
Manuscript Title:	[Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None  [NIH/NIA U19AG024904 NIH/NIA U01AG068057 NIH/NIA U24AG074855 NIH/NIA R01AG058676 Takeda Pharmaceutical Company Ltd	All to Institution  Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Siemens Medical Solutions USA, Inc DOD WW81XWH-19-1-0669	All to Institution All to Institution
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/14/2023
Your Name:	Ozlem Yardibi
Manuscript Title:	[Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial planning  None	Click the tab key to add additional rows.
		Time frame: past 36 mont	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	OV Talanda
		Takeda Pharmaceuticals	OY received stocks or stock options from Takeda Pharmaceuticals
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/7/2023
Your Name:	Prof Colin Masters
Manuscript Title:	[Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	-	t to the following statement to indicate your agreement to answered every question and have not altered the wo	

Date:	7/6/2023
Your Name:	Arthur A. Simen
Manuscript Title:	Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Medicine Approach to Clinical Trials in Sporadic Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-23-00542

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			T.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None     ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	As an employee of Takeda Development Center Americas, Inc. I own stock options in the company.	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None  I am a full-time employee of Takeda Development Center Americas, Inc.	
Plea [⊠]		t to the following statement to indicate your agreeme	Cufm a. De

Date	e:		7/6/2023	
You	r Name:		Walter A. Kukull	
Mar	nuscript Title:		[Identifying Individuals with Non-Alzheimer Approach to Clinical Trials in Sporadic Alz	r's Disease Co-pathologies: A Precision Medicine heimer's Disease
Manuscript Number (if known):		known):	ADJ-D-23-00542	
contaffe indicate The epic	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.		ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.	
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.		ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		ted NIH grants mentioned below	Click the tab key to add additional rows.
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).		one ants R01 AG058676 and U24 AG072122	
3	Royalties or licenses	⊠ No	one	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	ADRC External Advisory committees for: USC, BU, KU, and Icahn MSSM (NY)	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	-	t to the following statement to indicate your agreement y	

Date:	7/7/2023
Your Name: Michael W. Weiner  Manuscript Title: [Identifying Individuals with Non-Alzheimer's Disease Co-pathologies: A Precision Med Approach to Clinical Trials in Sporadic Alzheimer's Disease	
content of your manuscript. "Rela affected by the content of the ma	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be unuscript. Disclosure represents a commitment to transparency and does not necessarily at about whether to list a relationship/activity/interest, it is preferable that you do so.
• •	ies/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.
In item #1 below, report all supports	ort for the work reported in this manuscript without time limit. For all other items, the time 5 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	None   NIH Grant: 5R01AG058676-02   NIH Grant: 2 U19 AG024904.16	Payments were made to my institution. Payments were made to my institution. Click the tab key to add additional rows.
i	this item.		
		Time frame: past 36 mont	hs
2	Grants or contracts from	Time frame: past 36 mont	hs
2		[ ]	Payments were made to my institution.
2	contracts from	□ None	
2	contracts from any entity (if not	None None NIH Grant: 5U2CAG060426-04	Payments were made to my institution.
2	contracts from any entity (if not indicated in item	None  NIH Grant: 5U2CAG060426-04  NIH Grant: 1RF1AG059009-01	Payments were made to my institution.  Payments were made to my institution.
2	contracts from any entity (if not indicated in item	NIH Grant: 5U2CAG060426-04 NIH Grant: 1RF1AG059009-01 NIH Grant: R33 AG062867	Payments were made to my institution. Payments were made to my institution. Payments were made to my institution.
2	contracts from any entity (if not indicated in item	None  NIH Grant: 5U2CAG060426-04  NIH Grant: 1RF1AG059009-01  NIH Grant: R33 AG062867  NIH Grant: 1R01NS119651-01	Payments were made to my institution.
2	contracts from any entity (if not indicated in item	None  NIH Grant: 5U2CAG060426-04  NIH Grant: 1RF1AG059009-01  NIH Grant: R33 AG062867  NIH Grant: 1R01NS119651-01  NIH Grant: RF1AG062196	Payments were made to my institution.
2	contracts from any entity (if not indicated in item	None  NIH Grant: 5U2CAG060426-04  NIH Grant: 1RF1AG059009-01  NIH Grant: R33 AG062867  NIH Grant: 1R01NS119651-01  NIH Grant: RF1AG062196  NIH Grant: R56AG075744-01A1  Additional support from Department of Defense	Payments were made to my institution.
2	contracts from any entity (if not indicated in item	None  NIH Grant: 5U2CAG060426-04 NIH Grant: 1RF1AG059009-01 NIH Grant: 1R01NS119651-01 NIH Grant: 1R01NS119651-01 NIH Grant: RF1AG062196 NIH Grant: R56AG075744-01A1 Additional support from Department of Defense (DOD) Additional support from: California Department	Payments were made to my institution.
2	contracts from any entity (if not indicated in item	NIH Grant: 5U2CAG060426-04 NIH Grant: 1RF1AG059009-01 NIH Grant: R33 AG062867 NIH Grant: 1R01NS119651-01 NIH Grant: RF1AG062196 NIH Grant: R56AG075744-01A1 Additional support from Department of Defense (DOD) Additional support from: California Department of Public Health (CDPH)	Payments were made to my institution.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Additional support from: Alzheimer's Association	Payments were made to my institution.
		Additional support from: Johnson & Johnson	Payments were made to my institution.
		Additional support from: Kevin and Connie Shanahan	Payments were made to my institution.
		Additional support from: GE	Payments were made to my institution.
		Additional support from: VUmc	Payments were made to my institution.
		Additional support from: Australian Catholic University (HBI-BHR)	Payments were made to my institution.
		Additional support from: The Stroke Foundation	Payments were made to my institution.
		Additional support from: Veterans Administration	Payments were made to my institution.
3	Royalties or licenses	None	
4	Consulting fees	□ None	
		Boxer Capital	Payment was made directly to me.
		Cerecin	Payment was made directly to me.
		Clario/BioClinica	Payment was made directly to me.
		Dementia Society of Japan	Payment was made directly to me.
		Eisai	Payment was made directly to me.
		Guidepoint	Payment was made directly to me.
		Health and Wellness Partners	Payment was made directly to me.
		Indiana U.	Payment was made directly to me.
		LCN Consulting	Payment was made directly to me.
		Merck Sharp & Dohme Corp.	Payment was made directly to me.
		Duke U.	Payment was made directly to me.
		Prova Education	Payment was made directly to me.
		T3D Therapeutics	Payment was made directly to me.
		University of Southern CA (USC)	Payment was made directly to me.
		WebMD	Payment was made directly to me.
5	Payment or honoraria for	□ None	
	lectures,	China Association for Alzheimer's Disease (CAAD)	Payment was made directly to me.
	presentations,	Taipei Medical University	Payment was made directly to me.
	speakers	Cleveland Clinic	Payment was made directly to me.
	bureaus,	AD/PD Congress	Payment was made directly to me.
	manuscript	Foundation of Learning; Health Society (Japan)	Payment was made directly to me.
	writing or educational	INSPIRE Project; U. Toulouse	Payment was made directly to me.
	educational	Japan Society for Dementia Research	Payment was made directly to me.
	EVELLES	Korean Dementia Society	Payment was made directly to me.
		Merck Sharp & Dohme Corp.,	Payment was made directly to me.
		National Center for Geriatrics and Gerontology (NCGG; Japan	Payment was made directly to me.
		University of Southern California (USC)	Payment was made directly to me.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	[⊠] None	
7 Support for attending		□ None	
	meetings and/or travel	AD/PD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Cleveland Clinic	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		CTAD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Foundation of Learning; Health Society (Japan)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		INSPIRE Project; U. Toulouse	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Japan Society for Dementia Research	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Korean Dementia Society	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Merck Sharp & Dohme Corp.,	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		National Center for Geriatrics and Gerontology (NCGG; Japan	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		University of Southern California (USC)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
8	Patents planned, issued or	[⊠] None	
	pending		
9	Participation on a Data Safety	□ None	
	Monitoring Board or	ADNI Scientific Advisory Board	Leadership
	Advisory Board	UCSF Committee for Human Research	Committee Member
10	Leadership or	□ None	
	fiduciary role in other board,	UCSF Inclusion Diversity Equity & Awareness	Leadership
	society, committee or	Committee Diversity Task Force of the Alzheimer's Disease	Leadership
	advocacy group, paid or unpaid	Neuroimaging Initiative (ADNI)	
	1		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
		Alzeca	Stock options held.
		Alzheon, Inc.	Stock options held.
		ALZPath	Stock options held.
		Anven	Stock options held.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	[⊠] None	
Plea	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	